Aspergillosis Market

Market Overview:

The 7 major aspergillosis markets reached a value of US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.69% during 2024-2034.

The aspergillosis market has been comprehensively analyzed in IMARC's new report titled "Aspergillosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Aspergillosis refers to a type of fungal infection caused by a group of molds called Aspergillus. These molds are often present in the environment, such as in soil, decaying vegetation, indoor dust, etc. Most commonly, aspergillosis occurs in the form of allergic bronchopulmonary aspergillosis, invasive aspergillosis, chronic pulmonary aspergillosis, aspergilloma, sinus aspergillosis, and cutaneous aspergillosis. Some of the indications associated with the disease include fever, chest pain, cough, shortness of breath, fatigue, weight loss, etc. In many cases, aspergillosis can cause allergic reactions that can lead to symptoms such as wheezing, coughing, and skin rashes. The diagnostic process often involves a combination of medical history, physical examination, imaging tests, and laboratory tests. Doctors may order blood tests to check for signs of infection, as well as several imaging procedures, including X-rays or CT scans, to look for abnormalities in the lungs or other affected organs. A biopsy may also be performed to obtain a tissue sample for laboratory testing to confirm the presence of Aspergillus mold. Additionally, doctors may perform skin tests or measure levels of specific antibodies in the blood to help diagnose allergic reactions to Aspergillus.

The increasing prevalence of several associated risk factors, such as weakened immune systems, underlying lung diseases, prolonged corticosteroid use, environmental exposure to Aspergillus spores, intravenous drug use, etc., is primarily driving the aspergillosis market. Moreover, the emerging popularity of numerous antifungal medications, including azoles, echinocandins, amphotericin B, etc., which target the fungal cell wall, thereby disrupting the growth and reproduction of the fungus, is also creating a positive outlook for the market. Apart from this, the widespread adoption of galactomannan testing for the diagnosis of invasive aspergillosis in patients with hematological malignancies or undergoing hematopoietic stem cell transplantation is further bolstering the market growth. Additionally, various key players are making extensive investments in R&D activities to introduce new classes of drugs and formulations with improved efficacy and reduced toxicity. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the rising usage of nebulized antifungal therapy, which involves delivering antifungal drugs directly to the lungs through a nebulizer, for treating allergic bronchopulmonary aspergillosis, is expected to drive the aspergillosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the aspergillosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for aspergillosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the aspergillosis market in any manner.

Recent Developments:

• In March 2024, TFF Pharmaceuticals, Inc. released updated results from the Voriconazole Inhalation Powder (TFF VORI) phase 2 clinical trial studies for the management of invasive pulmonary aspergillosis (IPA). Data from the TFF VORI Phase 2 program demonstrated antifungal activity and a favorable safety and tolerability profile.
• In February 2024, Matinas BioPharma signed an agreement with the US FDA to develop a single Phase 3 registration trial of MAT2203 in patients with invasive aspergillosis who have limited therapy alternatives (the ORALTO trial).
• In December 2023, Basilea Pharmaceutica Ltd stated that its license partner Astellas Pharma US, Inc. (Astellas) had gained FDA approval for Cresemba (isavuconazole) for the treatment of invasive aspergillosis in pediatric patients. Cresemba injection is approved for adults and is now available to children patients aged one year and up. Cresemba pills are recommended for adults and pediatric patients aged 6 and above who weigh 16 kg or more.
• In June 2023, F2G Ltd. reported that the US FDA had given a Complete Response Letter (CRL) addressing the New Drug Application (NDA) for olorofim, an experimental antifungal, for the management of invasive fungal infections in patients with no or limited treatment alternatives.

Key Highlights:

• Allergic bronchopulmonary aspergillosis affects an estimated 5 million people worldwide each year. In contrast, invasive aspergillosis is significantly less prevalent, with an estimated 1 to 2 cases per 100,000 people.
• Allergic bronchopulmonary aspergillosis (ABPA) probably affects 1 to 15% of cystic fibrosis patients.
• According to research, 2.5% of adults with asthma also have ABPA, which amounts to around 4.8 million people worldwide.
• In a comprehensive assessment of intensive care unit autopsy studies, aspergillosis was identified as one of the top four most common diagnoses that probably led to death.
• In a major prospective research, persons with invasive aspergillosis had a one-year survival rate of 59% among solid organ transplant recipients and 25% amongst stem cell transplant recipients.

Drugs:

Isavuconazole refers to an intravenous (i.v.) and oral azole antifungal sold under the brand name Cresemba. Basilea has entered into multiple license and distribution agreements for isavuconazole, which covers over 115 countries. Also, in the 27 European Union member states, as well as in Norway, Iceland, Liechtenstein, and the United Kingdom, isavuconazole is approved for the treatment of adult patients with invasive aspergillosis.

Opelconazole (PC945) is a new antifungal medication intended for inhalation usage to enhance drug concentration in the lung while minimizing systemic exposure. Opelconazole was found to be well tolerated and produce exceptional therapeutic outcomes in a Special Needs study spanning numerous clinical locations in the United Kingdom. In this program, individuals with a variety of clinical characteristics who had previously failed antifungal treatment alternatives reacted effectively when opelconazole was added to their regimen.

SCY-078 is a novel triterpenoid glucan synthase inhibitor that inhibits Candida, Aspergillus, and Pneumocystis spp. It is now in clinical development to treat fungal infections.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the aspergillosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the aspergillosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current aspergillosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the aspergillosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the aspergillosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the aspergillosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of aspergillosis across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of aspergillosis by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of aspergillosis by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of aspergillosis by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with aspergillosis across the seven major markets?
• What is the size of the aspergillosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of aspergillosis?
• What will be the growth rate of patients across the seven major markets?
   

Aspergillosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for aspergillosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the aspergillosis market?
• What are the key regulatory events related to the aspergillosis market?
• What is the structure of clinical trial landscape by status related to the aspergillosis market?
• What is the structure of clinical trial landscape by phase related to the aspergillosis market?
• What is the structure of clinical trial landscape by route of administration related to the aspergillosis market?